Pharmakokinetik und -dynamik einer Langzeitinfusion mit dem anti-GD2 Antikörper ch14.18/CHO bei Patienten mit einem Hochrisiko-Neuroblastom

Dissertation, Universitätsmedizin der Universität Greifswald, 2021

Gespeichert in:
Bibliographische Detailangaben
1. Verfasser: Endres, Stefanie Katharina (VerfasserIn)
Körperschaft: Universität Greifswald (Grad-verleihende Institution)
Weitere Verfasser: Lode, Holger (AkademischeR BetreuerIn), Hundsdörfer, Patrick (AkademischeR BetreuerIn)
Format: UnknownFormat
Sprache:ger
Veröffentlicht: Greifswald 2020
Schlagworte:
Hochschulschrift > Neuroblastom > Immuntherapie > Ganglioside > Antikörper > Pharmakokinetik > Pharmakodynamik
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dissertation, Universitätsmedizin der Universität Greifswald, 2021
Immuntherapie, Neuroblastom, GD2, ch14.18/CHO, immunotherapy, neuroblastoma
Every year about 130 children in Germany develope neuroblastoma. With a share of 7% of all malignant tumour diseases in childhood, it thus represents the most common solid extracranial tumour in children under the age of 15. Unfortunately, by the time of initial diagnosis, one in two neuroblastomas has metastasised and the diagnosis for advanced stages is still particularly poor. Improving the life expectancy and quality of life of these patients is therefore of great importance and the subject of current research. In recent years, great successes have already been achieved in the field of tumour immunology. The monoclonal antibody ch14.18/CHO (dinutuximab beta), which is directed against the tumour-associated antigen GD2 that is highly expressed on neuroblastoma cells, is used according to the principle of passive immunisation. The efficacy was confirmed in several clinical trials, but also showed considerable side effects of this therapy, especially in the form of neuropathic pain. This paper shows the results of a unicentre programme conducted at the University of Greifswald with the aim of reducing side effects by changing the mode of application. A prolonged continuous infusion of ch14.18/CHO was administered in combination with subcutaneous application of proleukin (IL-2) and oral isotretinoin (13-cis-RA) administration. Measured by the pain intensity and the morphine requirement of the patients, a low pain level with a strong downward trend during the course of therapy ...
Beschreibung:Literaturverzeichnis: Seite 66-73
Beschreibung:VII, 82 Blätter
Diagramme (teilweise farbig)